REgiStry-based Cardiovascular qUality improvEment Research

Inclusion Criteria

• •Patients aged ≥ 18 years with cardiovascular diseases who are hospitalized at the Department of Cardiology of Peking University Third Hospital after April 24th, 2023;
• •Patients meet the following disease definitions:
• •1. PCI group: Patients underwent percutaneous coronary intervention (PCI) or coronary angiography;
• •2. HF group: Patients diagnosed with heart failure;
• •3. Cardiometabolic Disease (CMD) group: Patients with cardiovascular disease (primarily including coronary artery disease, peripheral artery disease, and aortic disease) and coexisting metabolic disorder (defined as obesity \[BMI≥28 kg/m\^2\], prediabetes and diabetes, hypertension, hyperlipidemia, thyroid dysfunction, and non-alcoholic fatty liver disease);
• •4. Structural Heart Disease (SHD): Patients with structural heart disease, including
• •* Congenital heart diseases (such as ventricular septal defect, atrial septal defect, patent ductus arteriosus, tetralogy of Fallot, etc.);
• •* Heart valve diseases (mitral valve, tricuspid valve, aortic valve, pulmonary valve, etc.);
• •* Cardiomyopathies (hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.);
• •* Conditions associated with other diseases or acquired structural abnormalities of the heart (ventricular septal perforation, ventricular aneurysm, iatrogenic atrial septal defect, etc.);
• •* Conditions resulting from other diseases that cause abnormal heart function, which can be corrected by altering cardiovascular structure (such as left atrial appendage dysfunction caused by atrial fibrillation, abnormal cardiac function caused by heart failure);
• •* Others: Intracardiac thrombosis, cardiac tumors, pericardial diseases, etc.